| 词条 | Vismodegib |
| 释义 |
| IUPAC_name = 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide | image = Vismodegib2DACS.svg | pronounce = {{IPAc-en|ˌ|v|ɪ|s|m|oʊ|ˈ|d|ɛ|g|ɪ|b}} {{respell|VIS|moh|DEG|ib}} | tradename = Erivedge | Drugs.com = {{Drugs.com|monograph|erivedge}} | licence_EU = yes | licence_US = Vismodegib | pregnancy_AU = X |pregnancy_AU_comment=[1] | pregnancy_US = X |pregnancy_US_comment=[2] | pregnancy_category = | legal_AU = S4 | legal_CA = Rx-only | legal_UK = POM | legal_US = Rx-only | legal_status = | routes_of_administration = By mouth (capsules) | bioavailability = 31.8% | protein_bound = >99% | metabolism = <2% metabolised by CYP2C9, CYP3A4, CYP3A5 | elimination_half-life = 4 days (continuous use), 12 days (single dose) | excretion = Fecal (82%), Urinary (4.4%) | IUPHAR_ligand = 6975 | CAS_number = 879085-55-9 | ATC_prefix = L01 | ATC_suffix = XX43 | PubChem = 24776445 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 66903 | ChEMBL = 473417 | UNII = 25X868M3DS | DrugBank = DB08828 | ChemSpiderID = 23337846 | KEGG = D09992 | synonyms = GDC-0449, RG-3616 | C=19 | H=14 | Cl=2 | N=2 | O=3 | S=1 | molecular_weight = 421.30 g/mol | smiles = CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl | StdInChI = 1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) | StdInChIKey = BPQMGSKTAYIVFO-UHFFFAOYSA-N }} Vismodegib (trade name Erivedge {{IPAc-en|ˈ|ɛr|ɪ|v|ɛ|dʒ}} {{respell|ERR|i-vej}}) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval.[3] The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma {{as of |2011|6|lc=on}}.[4] The drug was developed by the biotechnology/pharmaceutical company Genentech, which is headquartered at South San Francisco, California, USA. IndicationVismodegib is indicated for patients with basal cell carcinoma (BCC) which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.[4][5] Mechanism of actionThe substance acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway.[4] SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway.[6] This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas. Side effectsIn clinical trials, common adverse effects included gastrointestinal disorders (nausea, vomiting, diarrhoea, constipation), muscle spasms, fatigue, hair loss, and dysgeusia (distortion of the sense of taste). The effects were mostly mild to moderate.[7] See also
References1. ^{{Drugs.com|pro|erivedge}} [8]2. ^{{Drugs.com|pro|erivedge}} 3. ^{{cite web | title=Vismodegib, First Hedgehog Inhibitor, Approved for BCC Patients | url=http://www.onclive.com/web-exclusives/Vismodegib-First-Hedgehog-Inhibitor-Approved-for-BCC-Patients-}} 4. ^{{cite web |title=FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma | url=http://www.roche.com/media/media_releases/med-cor-2012-01-30.htm }} 5. ^{{cite book|last1=Lacroix|first1=Marc|title=Targeted Therapies in Cancer|date=2014|publisher=Nova Sciences Publishers|location=Hauppauge , NY|isbn=978-1-63321-687-7|url=https://www.novapublishers.com/catalog/product_info.php?products_id=50994}} 6. ^{{cite web | url=http://www.biooncology.com/pipeline-molecules/vismodegib/index.html | title=Vismodegib (GDC-0449) Smoothened Inhibitor - BioOncology}} 7. ^{{Drugs.com|pro|erivedge}} 8. ^1 2 {{cite journal|url=http://www.prous.com/molecules/default.asp?ID=210|title=Molecule of the Month|date=June 2011}} }} External links
7 : Benzanilides|Chloroarenes|Pyridines|Sulfones|Teratogens|Antineoplastic drugs|Genentech |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。